Program Description
Bispecific antibody (BsAb) therapy has expanded treatment options in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). However, its distinct toxicities, primarily cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), require proactive recognition and management. Safe administration relies on structured dosing schedules, monitoring protocols, and clear escalation pathways. As toxicity mitigation evolves, so must practical guidance used to develop protocols, coordinate monitoring, and support timely intervention. Building on the clinical evidence reviewed in webinar 1, this session focuses on practical management of BsAb toxicities, covering the recognition and grading of CRS and ICANS using American Society for Transplantation and Cellular Therapy (ASTCT) criteria, mitigation and monitoring strategies, site-of-care decisions, and evidence-based protocol development aligned with published guidelines to support the safe integration of these therapies into practice.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: December 15, 2026
Expiration date: February 15, 2027
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Apply the American Society for Transplantation and Cellular Therapy (ASTCT) grading criteria to classify the clinical presentation of bispecific antibody (BsAb)–associated cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).
- Evaluate current site-level BsAb toxicity management approaches against published guidelines and evidence-based standards.
- Develop BsAb toxicity management protocols based on regimen selection and patient comorbidities.
Brooke Adams, PharmD, BCOP
Clinical Pharmacy Specialist
Orlando Health
Orlando, FL
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number [UAN pending]. The activity is available for CE credit through February 15, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
has no relevant financial relationships with ineligible companies to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Emily Tyler; and Brianna Winters have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms